STOCK TITAN

Fulcrum Therapeutics, Inc. - FULC STOCK NEWS

Welcome to our dedicated news page for Fulcrum Therapeutics (Ticker: FULC), a resource for investors and traders seeking the latest updates and insights on Fulcrum Therapeutics .

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Fulcrum Therapeutics 's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Fulcrum Therapeutics 's position in the market.

Rhea-AI Summary
Fulcrum Therapeutics, Inc.® (Nasdaq: FULC) announces participation in investor conferences. The company will be presenting at the Stifel Healthcare Conference on November 14, 2023, and at the Piper Sandler 35th Annual Healthcare Conference on November 30, 2023. Live webcasts and replays will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-18.71%
Tags
conferences
-
Rhea-AI Summary
Fulcrum Therapeutics, Inc.® completed enrollment in the Phase 3 REACH trial of losmapimod in facioscapulohumeral muscular dystrophy (FSHD) and expects to report topline data in the fourth quarter of 2024. The U.S. Food and Drug Administration (FDA) lifted the clinical hold for pociredir (formerly FTX-6058) in sickle cell disease (SCD), and trial reinitiation is underway. The company's cash runway has been extended into 2026. Fulcrum also reported financial results for the third quarter of 2023 and provided a business update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.5%
Tags
-
Rhea-AI Summary
Fulcrum Therapeutics, Inc.® will release its Q3 2023 financial results on November 7, 2023. The company is focused on developing small molecules for rare genetic diseases. A conference call and webcast will be held at 8:00 a.m. ET to discuss the results and provide corporate updates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.66%
Tags
conferences earnings
Rhea-AI Summary
Fulcrum Therapeutics to participate in fireside chat at Cantor Fitzgerald Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.96%
Tags
conferences
-
Rhea-AI Summary
Fulcrum Therapeutics grants non-statutory stock options to new employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Fulcrum Therapeutics completes enrollment in Phase 3 clinical trial for FSHD treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.07%
Tags
Rhea-AI Summary
Fulcrum Therapeutics receives FDA approval to resume clinical development of FTX-6058 for sickle-cell disease treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
38.52%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.79%
Tags
Rhea-AI Summary
Fulcrum Therapeutics, Inc. (Nasdaq: FULC) appoints Alan A. Musso as CFO effective August 7, 2023. With 30 years of life sciences industry experience, Mr. Musso brings valuable financial and operational leadership to the clinical-stage biopharmaceutical company. His appointment is aimed at advancing the company's mission of delivering transformative therapies for genetically defined rare diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.79%
Tags
management
Fulcrum Therapeutics, Inc.

Nasdaq:FULC

FULC Rankings

FULC Stock Data

455.59M
38.46M
1.38%
99.44%
3.65%
Medicinal and Botanical Manufacturing
Manufacturing
Link
United States of America
CAMBRIDGE

About FULC

what if we could regulate genes, not just discover them? what if we could treat disease at their genetic source? what if we could integrate multiple disciplines to develop breakthrough medicines? what if you could be a part of a passionate team committed to the patients we serve? we can. we will. we are. join us. we are here to develop new medicines to deliver a new future for patients and their families by transforming gene regulation in disease. a fulcrum is defined as the point on which a lever rests, balances and pivots. fulcrum therapeutics is intervening in gene regulatory mechanisms to unlock the information contained in the human genome. the fulcrum product engine is dedicated to bringing balance to the genetic on and off switches in disease. our approach the sequencing of the human genome has provided incredible insight into disease biology, yet the richness of biology comes from the dynamic on and off switches that control the genome – gene regulation. the fulcrum product eng